Top

Published in:

Open Access 01-05-2017 | Original Paper

Immunological memory to hyperphosphorylated tau in asymptomatic individuals

Authors: Gabriel Pascual, Jehangir S. Wadia, Xueyong Zhu, Elissa Keogh, Başak Kükrer, Jeroen van Ameijde, Hanna Inganäs, Berdien Siregar, Gerrard Perdok, Otto Diefenbach, Tariq Nahar, Imke Sprengers, Martin H. Koldijk, Els C. Brinkman-van der Linden, Laura A. Peferoen, Heng Zhang, Wenli Yu, Xinyi Li, Michelle Wagner, Veronica Moreno, Julie Kim, Martha Costa, Kiana West, Zara Fulton, Lucy Chammas, Nancy Luckashenak, Lauren Fletcher, Trevin Holland, Carrie Arnold, R. Anthony Williamson, Jeroen J. Hoozemans, Adrian Apetri, Frederique Bard, Ian A. Wilson, Wouter Koudstaal, Jaap Goudsmit

Published in: Acta Neuropathologica | Issue 5/2017

Abstract

Several reports have described the presence of antibodies against Alzheimer’s disease-associated hyperphosphorylated forms of tau in serum of healthy individuals. To characterize the specificities that can be found, we interrogated peripheral IgG⁺ memory B cells from asymptomatic blood donors for reactivity to a panel of phosphorylated tau peptides using a single-cell screening assay. Antibody sequences were recovered, cloned, and expressed as full-length IgGs. In total, 52 somatically mutated tau-binding antibodies were identified, corresponding to 35 unique clonal families. Forty-one of these antibodies recognize epitopes in the proline-rich and C-terminal domains, and binding of 26 of these antibodies is strictly phosphorylation dependent. Thirteen antibodies showed inhibitory activity in a P301S lysate seeded in vitro tau aggregation assay. Two such antibodies, CBTAU-7.1 and CBTAU-22.1, which bind to the proline-rich and C-terminal regions of tau, respectively, were characterized in more detail. CBTAU-7.1 recognizes an epitope that is similar to that of murine anti-PHF antibody AT8, but has different phospho requirements. Both CBTAU-7.1 and CBTAU-22.1 detect pathological tau deposits in post-mortem brain tissue. CBTAU-7.1 reveals a similar IHC distribution pattern as AT8, immunostaining (pre)tangles, threads, and neuritic plaques. CBTAU-22.1 shows selective detection of neurofibrillary changes by IHC. Taken together, these results suggest the presence of an ongoing antigen-driven immune response against tau in healthy individuals. The wide range of specificities to tau suggests that the human immune repertoire may contain antibodies that can serve as biomarkers or be exploited for therapy.

Available only for authorised users

Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, Terwilliger TC, Urzhumtsev A, Zwart PH, Adams PD (2012) Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 68:352–367. doi:10.1107/S0907444912001308 CrossRefPubMedPubMedCentral

Alafuzoff I, Pikkarainen M, Neumann M, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Graeber MB, Hortobagyi T, Ince PG, Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C, Nilsson T, Parchi P, Patsouris E, Revesz T, Roggendorf W, Rozemuller A, Seilhean D, Streichenberger N, Thal DR, Wharton SB, Kretzschmar H (2015) Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. J Neural Transm 122:957–972. doi:10.1007/s00702-014-1304-1 CrossRefPubMed

Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22:9340–9351PubMed

Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 103:26–35CrossRefPubMed

Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 98:10037–10041. doi:10.1073/pnas.181342398181342398 CrossRefPubMedPubMedCentral

Barthelemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, Buee L, Gabelle A, Junot C, Lehmann S, Becher F (2016) Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res 15:667–676. doi:10.1021/acs.jproteome.5b01001 CrossRefPubMed

Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M et al (1992) The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 11:1593–1597PubMedPubMedCentral

Billingsley ML, Kincaid RL (1997) Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 323(Pt 3):577–591CrossRefPubMedPubMedCentral

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed

10.

Bujotzek A, Lipsmeier F, Harris SF, Benz J, Kuglstatter A, Georges G (2016) VH-VL orientation prediction for antibody humanization candidate selection: A case study 8:288–305. doi:10.1080/19420862.2015.1117720

11.

Concepcion J, Witte K, Wartchow C, Choo S, Yao D, Persson H, Wei J, Li P, Heidecker B, Ma W, Varma R, Zhao LS, Perillat D, Carricato G, Recknor M, Du K, Ho H, Ellis T, Gamez J, Howes M, Phi-Wilson J, Lockard S, Zuk R, Tan H (2009) Label-free detection of biomolecular interactions using BioLayer interferometry for kinetic characterization. Combinatorial Chem High Throughput Screen 12:791–800CrossRef

12.

Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Investig 120:1663–1673. doi:10.1172/JCI41902 CrossRefPubMedPubMedCentral

13.

Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL 3rd, Wisniewski T, Woltjer RL, Yamada M, Nelson PT (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755–766. doi:10.1007/s00401-014-1349-0 CrossRefPubMedPubMedCentral

14.

Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Roskam S, Stuer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M (2011) Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer’s disease. J Neurosci 31:5847–5854. doi:10.1523/JNEUROSCI.4401-10.2011 CrossRefPubMed

15.

Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141–1154CrossRefPubMedPubMedCentral

16.

Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57:801–805CrossRefPubMed

17.

Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486–501. doi:10.1107/S0907444910007493 CrossRefPubMedPubMedCentral

18.

Fialova L, Bartos A, Svarcova J, Malbohan I (2011) Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. PLoS ONE 6:e27476. doi:10.1371/journal.pone.0027476 CrossRefPubMedPubMedCentral

19.

Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI (2015) Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J Biol Chem 290:21652–21662. doi:10.1074/jbc.M115.657924 CrossRefPubMedPubMedCentral

20.

Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, Ni I, Mei L, Sundar PD, Day GM, Cox D, Rajpal A, Pons J (2009) Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 106:20216–20221. doi:10.1073/pnas.0909775106 CrossRefPubMedPubMedCentral

21.

Goedert M, Klug A, Crowther RA (2006) Tau protein, the paired helical filament and Alzheimer’s disease. J Alzheimer’s Dis 9:195–207CrossRef

22.

Greenberg SG, Davies P (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 87:5827–5831CrossRefPubMedPubMedCentral

23.

Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83:4913–4917CrossRefPubMedPubMedCentral

24.

Hanisch K, Soininen H, Alafuzoff I, Hoffmann R (2010) Analysis of human tau in cerebrospinal fluid. J Proteome Res 9:1476–1482. doi:10.1021/pr901002t CrossRefPubMed

25.

Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60:1119–1122. doi:10.1001/archneur.60.8.1119 CrossRefPubMed

26.

Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80:1778–1783. doi:10.1212/WNL.0b013e31828726f5 CrossRefPubMedPubMedCentral

27.

Henriksen K, Byrjalsen I, Christiansen C, Karsdal MA (2015) Relationship between serum levels of tau fragments and clinical progression of Alzheimer’s disease. J Alzheimer’s Dis 43:1331–1341. doi:10.3233/JAD-140984

28.

Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI (2014) Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci USA 111:E4376–E4385. doi:10.1073/pnas.1411649111 CrossRefPubMedPubMedCentral

29.

Hromadkova L, Kolarova M, Jankovicova B, Bartos A, Ricny J, Bilkova Z, Ripova D (2015) Identification and characterization of natural antibodies against tau protein in an intravenous immunoglobulin product. J Neuroimmunol 289:121–129. doi:10.1016/j.jneuroim.2015.10.017 CrossRefPubMed

30.

Inekci D, Henriksen K, Linemann T, Karsdal MA, Habib A, Bisgaard C, Eriksen FB, Vilholm OJ (2015) Serum fragments of tau for the differential diagnosis of Alzheimer’s disease. Curr Alzheimer Res 12:829–836CrossRefPubMed

31.

Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, Sato K, Kohno H, Imahori K (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease. Neurosci Lett 270:91–94CrossRefPubMed

32.

James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA (2014) Contribution of Alzheimer disease to mortality in the United States. Neurology 82:1045–1050. doi:10.1212/WNL.0000000000000240 CrossRefPubMedPubMedCentral

33.

Jicha GA, O’Donnell A, Weaver C, Angeletti R, Davies P (1999) Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase. J Neurochem 72:214–224CrossRefPubMed

34.

Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D (1997) The tau protein in human cerebrospinal fluid in Alzheimer’s disease consists of proteolytically derived fragments. J Neurochem 68:430–433CrossRefPubMed

35.

Kolarova M, Garcia-Sierra F, Bartos A, Ricny J, Ripova D (2012) Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimer’s Dis 2012:731526. doi:10.1155/2012/731526

36.

Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83:4044–4048CrossRefPubMedPubMedCentral

37.

Lerner RA (2016) Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol 16:498–508. doi:10.1038/nri.2016.67 CrossRefPubMed

38.

Lingwood D, McTamney PM, Yassine HM, Whittle JR, Guo X, Boyington JC, Wei CJ, Nabel GJ (2012) Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489:566–570. doi:10.1038/nature11371 CrossRefPubMed

39.

Malia TJ, Teplyakov A, Ernst R, Wu SJ, Lacy ER, Liu X, Vandermeeren M, Mercken M, Luo J, Sweet RW, Gilliland GL (2016) Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8. Proteins 84:427–434. doi:10.1002/prot.24988 CrossRefPubMedPubMedCentral

40.

41.

Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harbor Perspect Med 2:a006247. doi:10.1101/cshperspect.a006247 CrossRef

42.

McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biolo Crystallogr 61:458–464. doi:10.1107/S0907444905001617 CrossRef

43.

Mengel D, Roskam S, Neff F, Balakrishnan K, Deuster O, Gold M, Oertel WH, Bacher M, Bach JP, Dodel R (2013) Naturally occurring autoantibodies interfere with beta-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer’s disease 24 h after single treatment. Transl Psychiatry 3:e236. doi:10.1038/tp.2012.151 CrossRefPubMedPubMedCentral

44.

Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF (2013) Characterization of novel CSF Tau and ptau biomarkers for Alzheimer’s disease. PLoS ONE 8:e76523. doi:10.1371/journal.pone.0076523 CrossRefPubMed

45.

Pappas L, Foglierini M, Piccoli L, Kallewaard NL, Turrini F, Silacci C, Fernandez-Rodriguez B, Agatic G, Giacchetto-Sasselli I, Pellicciotta G, Sallusto F, Zhu Q, Vicenzi E, Corti D, Lanzavecchia A (2014) Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516:418–422. doi:10.1038/nature13764 CrossRefPubMed

46.

Peeraer E, Bottelbergs A, Van Kolen K, Stancu IC, Vasconcelos B, Mahieu M, Duytschaever H, Ver Donck L, Torremans A, Sluydts E, Van Acker N, Kemp JA, Mercken M, Brunden KR, Trojanowski JQ, Dewachter I, Lee VM, Moechars D (2015) Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol Dis 73:83–95. doi:10.1016/j.nbd.2014.08.032 CrossRefPubMed

47.

Porzig R, Singer D, Hoffmann R (2007) Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun 358:644–649. doi:10.1016/j.bbrc.2007.04.187 CrossRefPubMed

48.

Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M (2006) Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer’s disease and healthy subjects. Neurosci Lett 410:90–93. doi:10.1016/j.neulet.2006.01.072 CrossRefPubMed

49.

Sanchez C, Diaz-Nido J, Avila J (2000) Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Prog Neurobiol 61:133–168CrossRefPubMed

50.

Selkoe DJ (1989) Amyloid beta protein precursor and the pathogenesis of Alzheimer’s disease. Cell 58:611–612CrossRefPubMed

51.

Selkoe DJ (1993) Physiological production of the beta-amyloid protein and the mechanism of Alzheimer’s disease. Trends Neurosci 16:403–409CrossRefPubMed

52.

Shih HH, Tu C, Cao W, Klein A, Ramsey R, Fennell BJ, Lambert M, Ni Shuilleabhain D, Autin B, Kouranova E, Laxmanan S, Braithwaite S, Wu L, Ait-Zahra M, Milici AJ, Dumin JA, LaVallie ER, Arai M, Corcoran C, Paulsen JE, Gill D, Cunningham O, Bard J, Mosyak L, Finlay WJ (2012) An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition. J Biol Chem 287:44425–44434. doi:10.1074/jbc.M112.415935 CrossRefPubMedPubMedCentral

53.

Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K (2001) Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 70:624–630CrossRefPubMedPubMedCentral

54.

Smith LM, Coffey MP, Klaver AC, Loeffler DA (2013) Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein. Int Immunopharmacol 16:424–428. doi:10.1016/j.intimp.2013.04.034 CrossRefPubMed

55.

Smith LM, Coffey MP, Loeffler DA (2014) Specific binding of intravenous immunoglobulin products to tau peptide fragments. Int Immunopharmacol 21:279–282. doi:10.1016/j.intimp.2014.05.009 CrossRefPubMed

56.

Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Str Mol Biol 16:265–273. doi:10.1038/nsmb.1566 CrossRef

57.

Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800CrossRefPubMed

58.

Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM⁺ memory B cells. PLoS ONE 3:e3942. doi:10.1371/journal.pone.0003942 CrossRefPubMedPubMedCentral

59.

Uchihara T (2007) Silver diagnosis in neuropathology: principles, practice and revised interpretation. Acta Neuropathol 113:483–499. doi:10.1007/s00401-007-0200-2 CrossRefPubMedPubMedCentral

60.

Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K (2013) Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimer’s Dis 33(Suppl 1):S123–S139. doi:10.3233/JAD-2012-129031

61.

Weuve J, Hebert LE, Scherr PA, Evans DA (2014) Deaths in the United States among persons with Alzheimer’s disease (2010–2050). Alzheimer’s Dementia 10:e40–e46. doi:10.1016/j.jalz.2014.01.004 CrossRefPubMedPubMedCentral

62.

Wood JG, Mirra SS, Pollock NJ, Binder LI (1986) Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci USA 83:4040–4043CrossRefPubMedPubMedCentral

63.

Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O’Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Medicine 208:181–193. doi:10.1084/jem.20101352 CrossRef

64.

Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667–671. doi:10.1038/nature06890 CrossRefPubMedPubMedCentral

65.

Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80:402–414. doi:10.1016/j.neuron.2013.07.046 CrossRefPubMedPubMedCentral

Title: Immunological memory to hyperphosphorylated tau in asymptomatic individuals
Authors: Gabriel Pascual
Jehangir S. Wadia
Xueyong Zhu
Elissa Keogh
Başak Kükrer
Jeroen van Ameijde
Hanna Inganäs
Berdien Siregar
Gerrard Perdok
Otto Diefenbach
Tariq Nahar
Imke Sprengers
Martin H. Koldijk
Els C. Brinkman-van der Linden
Laura A. Peferoen
Heng Zhang
Wenli Yu
Xinyi Li
Michelle Wagner
Veronica Moreno
Julie Kim
Martha Costa
Kiana West
Zara Fulton
Lucy Chammas
Nancy Luckashenak
Lauren Fletcher
Trevin Holland
Carrie Arnold
R. Anthony Williamson
Jeroen J. Hoozemans
Adrian Apetri
Frederique Bard
Ian A. Wilson
Wouter Koudstaal
Jaap Goudsmit
Publication date: 01-05-2017
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 5/2017
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-017-1705-y

At a glance: The STEP trials

Springer Medicine

Immunological memory to hyperphosphorylated tau in asymptomatic individuals

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid

Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network

Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia

Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers

Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment

Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo